Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04262141 · ClinicalTrials.gov registry record · Phase 2
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
A Phase 2 study of Polycythemia Vera and Essential Thrombocythemia, sponsored by Terrence J Bradley, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04262141: Active Phase 2 study of Polycythemia Vera and Essential Thrombocythemia, sponsored by Terrence J Bradley, MD.
NCT04262141 is a Phase 2 study of Polycythemia Vera and Essential Thrombocythemia that is active but no longer recruiting, run by Terrence J Bradley, MD. The registered enrollment target is 4 participants, below the 340-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04262141, a Phase 2 study of Polycythemia Vera and Essential Thrombocythemia, is active but no longer recruiting, sponsored by Terrence J Bradley, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.
Primary Outcome
As evaluated by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) response criteria.
Conditions Studied
Interventions
- DRUG IMG-7289
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 2 |
What the registry record for NCT04262141 still lists
NCT04262141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 340-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Polycythemia Vera appearing as the primary indexed condition, and to 1 intervention - of which IMG-7289 is the first listed.
NCT04262141 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04262141 about?
NCT04262141 is a clinical study titled "IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)". The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.
What is the current status of trial NCT04262141?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2020-10-02. Estimated completion is 2027-10-31.
What conditions does trial NCT04262141 study?
This clinical trial studies the following conditions: Polycythemia Vera, Essential Thrombocythemia.
What interventions are being tested in trial NCT04262141?
The interventions under investigation include: IMG-7289 (DRUG).
Who is sponsoring clinical trial NCT04262141?
This trial is sponsored by Terrence J Bradley, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04262141 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04262141's enrollment target sits among peer trials
4 23rd of 22 the lowest of 22 other Polycythemia Vera trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polycythemia Vera trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Ruxolitinib in Thrombocythemia and Polycythemia Vera
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI